Cardiovascular and Metabolic Disease Portfolio

cvmd-magnifyglass.png

"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

Cardiovascular and Metabolic Disease Portfolio

CrownBio’s CVMD portfolio is a unique continuum of translational platforms that enables our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development.

Our clients engage with these translational platforms to model human cardiovascular and metabolic disease pathologies and use them to predict human efficacy and safety of therapeutic candidates.

Translational Solutions Leader In:

CrownBio’s CVMD portfolio includes both rodent and non-human primate (NHP) models that can be used at various stages of preclinical research to enable critical go/no-go decisions.

Next Generation Technology Development: We actively develop the next generation of technologies to address unmet needs in CVMD research and ensure that we are always ready with a solution when our clients come to us with a problem.

A Strategic Drug Development Partner: Our broad portfolio of models and services, combined with leading scientific expertise helps our customers bridge the preclinical to clinical gap with high confidence and translationally sound scientific data.

Cardiovascular and Metabolic Disease Capabilities